Cromos Pharma, where the patients are

April 23, 2014 – News Bytes

Study Conduct

U.S. cancer researchers launching five-drug personalized medicines trial

By Ronald Rosenberg
CenterWatch Staff Writer

U.S. cancer researchers plan to launch a five-drug clinical trial for patients with advanced lung cancer in mid-May, in a public-private collaboration between several major cancer organizations and five pharmaceutical companies that marks the second American multi-drug research program into personalized medicines to treat different cancers.


The Pulse on Study Conduct By Elizabeth Weeks-Rowe

Everyone has the occasional poor performance in clinical research. Study coordinators may fail to report a serious adverse event. Monitors may overlook an incorrect version of an informed consent form. Without the occasional failure, we would not progress—in learning, adapting or growing as clinical researchers. Error is the most effective learning tool, with the dual outcomes of compliance and retention.


More Pulse articles... »
CRF Health eCOA webinar series
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.